Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Timothy R. Hurley"'
Autor:
Sergey Filippov, Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Jeffrey C. Hanselman, Clay T. Cramer, Rai Ajit K. Srivastava, Timothy R. Hurley, Cheryl D. Bradshaw, Mark A. Spahr, Roger S. Newton
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 8, Pp 2095-2108 (2013)
ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates le
Externí odkaz:
https://doaj.org/article/5dade5c025dd481597a6c9e3ada9030c
Autor:
Stephen L. Pinkosky, Sergey Filippov, Rai Ajit K. Srivastava, Jeffrey C. Hanselman, Cheryl D. Bradshaw, Timothy R. Hurley, Clay T. Cramer, Mark A. Spahr, Ashley F. Brant, Jacob L. Houghton, Chris Baker, Mark Naples, Khosrow Adeli, Roger S. Newton
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 1, Pp 134-151 (2013)
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and gluc
Externí odkaz:
https://doaj.org/article/cec4f54dcb2f41e99d4df80fe4b930fe
Publikováno v:
Nutrition, Metabolism and Cardiovascular Diseases. 32:290-293
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36734392645305cd0db63cfb55b5b56f
https://doi.org/10.1016/j.numecd.2021.10.002
https://doi.org/10.1016/j.numecd.2021.10.002
Autor:
Khosrow Adeli, Rai Ajit K. Srivastava, Timothy R. Hurley, Daniela Carmen Oniciu, Roger S. Newton
Publikováno v:
Nutrition, metabolism, and cardiovascular diseases : NMCD. 31(8)
Background and aims Cholesterol and triglycerides are risk factors for developing cardiovascular disease. Therefore, appropriate cells and assays are required to discover and develop dual cholesterol and fatty acid inhibitors. A predictive hyperlipid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a692e28f2880ede8ea0e159897b65738
https://pubmed.ncbi.nlm.nih.gov/34893416
https://pubmed.ncbi.nlm.nih.gov/34893416
Autor:
Cheryl D. Bradshaw, Sergey Filippov, Clay T. Cramer, Catherine Pawloski, Mark A. Spahr, Stephen L. Pinkosky, Timothy R. Hurley, Rai Ajit K. Srivastava, Richard J Lister, Roger S. Newton, Jeffrey C. Hanselman
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 8, Pp 2095-2108 (2013)
ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af69809908d091df0e381593e8a69ea9
http://www.sciencedirect.com/science/article/pii/S002222752037526X
http://www.sciencedirect.com/science/article/pii/S002222752037526X
Autor:
Mark A. Spahr, Jeffrey C. Hanselman, Roger S. Newton, Rai Ajit K. Srivastava, Mark Naples, Clay T. Cramer, Stephen L. Pinkosky, Timothy R. Hurley, Khosrow Adeli, Jacob L. Houghton, Sergey Filippov, Cheryl D. Bradshaw, Ashley F. Brant, Christopher Baker
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 1, Pp 134-151 (2013)
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and gluc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d7951a1d094c9e3e8454ac8eafbe26
https://doi.org/10.1194/jlr.m030528
https://doi.org/10.1194/jlr.m030528
Autor:
Timothy R. Hurley
Publikováno v:
Compensation & Benefits Review. 40:52-66
The difficulties entailed in VEBA plan design and implementation are easily outweighed by the advantages offered to both employers and employees.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62b3ae695dec1c3db5f8dfa387a2cd4b
https://doi.org/10.1177/0886368708324848
https://doi.org/10.1177/0886368708324848
Autor:
Timothy R. Hurley, Douglas K. Durham
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 30:1895-1901
Near and above overload concentrations of seven separate compounds were injected onto three separate C18 columns containing 1.7, 3.5, and 5.0 µm particles to determine “loadability” of the column during preparative chromatography. The columns di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7507ce0979566d982a1c36f22baef04a
https://doi.org/10.1080/10826070701386462
https://doi.org/10.1080/10826070701386462
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 28:917-924
Seven degradation products observed in formulated pregabalin have been characterized. These compounds result from Maillard reactions and Amadori rearrangements. Heating pregabalin in the presence of lactose formed significant quantities of these degr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9947bc76139692765928746595b30b
https://doi.org/10.1016/s0731-7085(01)00710-5
https://doi.org/10.1016/s0731-7085(01)00710-5
Autor:
Timothy R. Hurley, R. L. Stanfield, Maureen K. Anderson, Brian R. Krause, Drago Robert Sliskovic, Adele Bernabei, Patrick Michael O'brien, R. F. Bousley
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:295-300
The syntheses and biological activities for anilides derived from 2-phenyl-2-(dodecyl-2H-tetrazol-5-yl)acetic acid are described. Evidence is provided that one of these compounds, (+)- 8b , stereoselectively inhibits ACAT in vitro and possesses super
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deab38b81f1f99ae2d7f0c27e165ac6d
https://doi.org/10.1016/0960-894x(95)00025-o
https://doi.org/10.1016/0960-894x(95)00025-o